Economic evaluation of levosimendan versus dobutamine for the treatment of acute heart failure in Italy.
Adv Ther
; 29(12): 1037-50, 2012 Dec.
Article
em En
| MEDLINE
| ID: mdl-23233357
ABSTRACT
INTRODUCTION:
Inodilators are the first-choice class of drugs for the treatment of acute heart failure (AHF). Levosimendan is a relatively recent inodilatory agent, presenting superior outcomes in comparison with traditional inotropes.METHODS:
An economic evaluation of levosimendan for the treatment of AHF in Italy was performed. In a retrospective study conducted on patients with AHF admitted to a teaching hospital in Rome, two groups were derived from an observational registry 147 patients treated with levosimendan and 145 treated with dobutamine. Follow-up was at 1 year after treatment. In the reference study looked at in this paper, treatment with levosimendan reduced mean length of stay (LOS) by 1.5 days (P<0.05). Reduction in the rehospitalization rate was 6.7% (P<0.05). Mortality rate at 1 month was reduced by 4.8% (P<0.05).RESULTS:
Based on the reference study, a cost analysis from the hospital perspective was carried out. The incremental cost of treatment with levosimendan (697) was equivalent to the incremental savings (694), the latter being obtained from the reduction in LOS (508) and rehospitalization rate (186).CONCLUSION:
Despite the limitations of this study, and even neglecting all nonmonetary health gains as additional outcomes, levosimendan appears to be a competitive alternative compared with dobutamine for the treatment of AHF in the Italian hospital setting.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Piridazinas
/
Cardiotônicos
/
Dobutamina
/
Insuficiência Cardíaca
/
Hospitalização
/
Hidrazonas
Tipo de estudo:
Health_economic_evaluation
/
Observational_studies
Limite:
Humans
País como assunto:
Europa
Idioma:
En
Ano de publicação:
2012
Tipo de documento:
Article